Taisho


Also found in: Dictionary, Wikipedia.

Taishō

(tī`shō), 1879–1926, reign name of emperor of Japan (1912–26). His given name was Yoshihito. The son of Mutsuhito, the MeijiMeiji
, 1852–1912, reign name of the emperor of Japan from 1867 to 1912; his given name was Mutsuhito. He ascended the throne when he was 15. A year later the shogun fell, and the power that had been held by the Tokugawa military house was returned to the emperor.
..... Click the link for more information.
 emperor, he succeeded to the throne in 1912, but because of illness he played little part in governing the nation. His reign was characterized by democratization, friendly relations with the West, and economic growth. In 1921 Taishō was declared mentally incompetent and his son HirohitoHirohito
, 1901–89, emperor of Japan. He was made regent in 1921 and succeeded his father, Yoshihito (the Taishō emperor), in 1926. He married (1924) Princess Nagako Kuni (1903–2000); a son and heir, Prince Akihito, was born in 1933.
..... Click the link for more information.
 was made regent.

Taisho

 

(“Great Righteousness”), the reign name of the Japanese emperor Yoshihito (1912–26).

Taisho

1. the period of Japanese history and artistic style associated with the reign of Emperor Yoshihito (1912--26)
2. the throne name of Yoshihito (1879--1926), emperor of Japan (1912--26)
References in periodicals archive ?
In the meantime, Taisho Pharmaceutical and its subsidiary Taisho Toyama Pharmaceutical will continue to manufacture and sell the agent by signing a consignment contract with Sanofi-aventis Japan.
Taisho said it will entrust P&G with production of the product for the time being.
Taisho will distribute OTC-switched Zaditen as its Pabron series through pharmacies across Japan while Novartis Pharma will import it.
Taisho said it will pay a full-year dividend of 25 yen for the reporting year, unchanged from the previous year.
The release of the documents is expected to give momentum to research on Emperor Taisho, about whom there has so far been limited information.
Taisho and Merck are likely to sign a formal contract soon, and Merck will probably begin selling the drug in the United States around 2008 or 2009, the spokesman said.
Under the deal, one Taisho share was to be exchanged for one share in the new holding company, while one Tanabe share was to be swapped for 0.
Tokyo-based Taisho and Osaka-based Tanabe will create a holding company in April, and their individual strengths -- nonprescription drugs for Taisho and prescription drugs for Tanabe -- will be integrated under new firms to be set up by both next October under the holding firm, they said.
Under the agreement, a Japanese subsidiary of GSK will supply the product and Taisho will handle sales and distribution.
Taisho said it hopes the move will increase sales of Ripovitan D by introducing it to new customers.